NCT04512235 2026-04-07A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Alexion Pharmaceuticals, Inc.Phase 3 Active not recruiting281 enrolled